Can I read Milnacipran: The Clinical Properties of a Selective Serotonin and Noradrenaline Reuptake Inhibitor (SNRI) on EtoBox?

Milnacipran: The Clinical Properties of a Selective Serotonin and Noradrenaline Reuptake Inhibitor (SNRI) by Y. Lecrubier is a Medicine article available to read on EtoBox.

What is Milnacipran: The Clinical Properties of a Selective Serotonin and Noradrenaline Reuptake Inhibitor (SNRI) about?

Milnacipran is a novel antidepressant agent which selectively inhibits the reuptake of serotonin and noradrenaline without directly aecting postsynaptic receptor sites. The biochemical and pharmacological pro®le of milnacipran suggested that the drug would be therapeutically eective and well tolerated. This has been borne out by the results of placebo-controlled and open label trials of the antidepressant ecacy of milnacipran, as well as of comparative trials with tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). The designs and results of these studies are reviewed in this paper. Milnacipran is more eective than placebo in the treatment of major depressive episodes. It is equally eective as TCAs, but better tolerated. Milnacipran appears to be superior in ecacy to the SSRIs, particularly in patients with severe depression, and is equally well tolerated. The ecacy and tolerance pro®le of milnacipran re ̄ects its speci®c pharmacological activity. The eects of milnacipran are con®ned to the inhibition of serotonin and noradrenaline reuptake. There is no activity on postsynaptic receptors. Overall, milnacipran oers a bene®cial combination of good ec

Who reads Milnacipran: The Clinical Properties of a Selective Serotonin and Noradrenaline Reuptake Inhibitor (SNRI)?

Author

Y. Lecrubier

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0885-6222)

Published

1997

Language

EN

Field

Medicine (Health Sciences)